fda status bpc-157 compounding 2026 You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from Category 2 The FDA is considering allowing
Description
Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after daratumumab and BCMA-targeted therapies
Available from: Research C, for DE
New treatment options for irritable bowel syndrome with predominant diarrhea
C.MuntanerJ.MenndezM.AlonsoM.SchweitzerA.et al (2026)
Excessive nitric oxide production represents another theoretical concern
